enteric biomarkers with efficacy. Primary endpoints in part 2 are the association of ORR with baseline tissue and blood TMB; secondary endpoints are ORR, PFS, OS, safety, and the association of enteric biomarkers with efficacy.
Background: Nintedanib is an oral, triple angiokinase inhibitor approved by the EMA and other countries in combination with docetaxel for the treatment of adenocarcinoma NSCLC patients after first-line chemotherapy. Nintedanib plus docetaxel demonstrated significant and clinically meaningful OS benefits in adenocarcinoma patients, which were more pronounced in patients with aggressive or refractory tumors. During the past years the treatment landscape for advanced NSCLC has changed tremendously impacting individual treatment decisions and choice of adequate treatment sequences. Here we present the ongoing NIS VARGADO study design and set up to assess the efficacy and tolerability of nintedanib plus docetaxel in daily clinical routine in Germany. Trial design: The NIS VARGADO (NCT02392455) is currently recruiting patients. Four hundred patients are planned to be enrolled at one hundred German centers. Adult NSCLC patients with advanced adenocarcinoma who are initiating treatment with nintedanib according to its label as part of routine clinical practice are eligible. The primary endpoint of the study is the one-year overall survival rate after start of therapy with nintedanib and docetaxel. Progression-free survival is one of the key secondary endpoints. Patients with aggressive or refractory tumors will be analyzed in detail with respect to efficacy in this real world setting. Documentation of patients treated with nintedanib plus docetaxel combination following first-line chemotherapy and/or immunotherapy will allow for analyses on treatment sequence. Analysis of tolerability will comprise the assessment of frequency and severity of adverse events. Furthermore, therapy management under routine conditions will be recorded and assessed. Trial design: In this trial, 412 patients will be randomly assigned in a 1:1 ratio, to receive either carboplatin-pemetrexed chemotherapy,OR receive SHR-1210 combined with carboplatin-pemetrexed chemotherapy. Randomization will be stratified according to gender and smoking history. All the patients will receive carboplatin(area under the curve 5) plus pemetrexed(500 mg/m 2 ), all administered as IV infusion on Day 1 of each 3-week cycle for 4 or 6 cycles of the investigator's choice, followed by pemetrexed(500 mg/m 2 ) every 3 weeks(Q3W) maintenance for the remainder of the study. Patients assigned to the SHR-1210 combined with chemotherapy arm, will additionally receive SHR-1210(200mg) administered as IV infusion on Day 1 of each 3-week cycle, for up to 35 cycles. Patients assigned to the chemotherapy arm will have the opportunity to crossover to receive SHR-1210(200mg) monotherapy every 3 weeks(Q3W) once they experience progression of disease (PD) defined by RECIST 1.1 and meet all crossover criteria. Clinical trial identification: NCT03134872. Legal entity responsible for the study: Jiangsu HengRui Medicine Co., Ltd. Translational Development, Daiichi Sankyo Inc., Basking Ridge, NJ, USA, Background: In patients with metastatic EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC), resistance to EGFR tyrosine kinase inhibitors (TKIs) arises from the T790M EGFR mutation in over half of cases; up-regulation of "bypass track" activity in non-EGFR signaling pathways is observed in other cases. Up-regulation of expression of the AXL tyrosine kinase has been observed in EGFRm NSCLC patients experiencing disease progression on erlotinib, and xenograft studies have supported the role of AXL inhibition in combination with EGFR TKI treatment in overcoming such resistance. DS-1205c is a novel, orally administered, specific small molecule inhibitor of AXL. Trial design: This is a multicenter, open-label, Phase 1, dose escalation and dose expansion study of DS-1205c in combination with osimertinib in metastatic or unresectable EGFR-mutant NSCLC subjects experiencing disease progression during treatment with erlotinib, gefitinib, or afatinib, and without T790M resistance mutation; or during treatment with osimertinib. Eligible subjects are at least 18 years of age, have ECOG PS 0 or 1, have radiological documentation of disease progression on erlotinib, gefitinib, afatinib, or osimertinib, and have at least one measurable lesion. This study includes two parts: Dose Escalation and Dose Expansion. In Dose Escalation, subjects receive DS-1205c during a run-in period, followed by combination treatment with DS-1205c and 80 mg daily of osimertinib. Escalation of DS-1205c dosing is guided by the modified Continuous Reassessment Method using a Bayesian logistic regression model following the escalation with overdose control principle. In Dose Expansion, subjects receive DS-1205c at the recommended dose for expansion (RDE) determined in Dose Escalation, in combination with 80 mg daily of osimertinib. Primary objectives are to determine safety, tolerability, and RDE of DS-1205c in combination with osimertinib. Secondary objectives are to assess pharmacokinetic parameters of DS-1205a (free form of DS-1205c), osimertinib, and osimertinib active metabolites, and to assess antitumor activity (RECIST v1.1). Retrospective analysis of AXL expression will be conducted using tumor tissue collected prior to study treatment. Enrollment opened in December 2017. Clinical trial identification: NCT03255083. 
